AMR Kansas City Oncology

AMR Kansas City is a premier clinical research site and a key member of the Alliance for Multispecialty Research (AMR) network. Following the acquisition of AMR by Eligo Health Research in 2022, the site has expanded its capabilities in providing high-quality clinical trial services. The facility specializes in Phase I through IV clinical trials, with a particular focus on oncology, infectious diseases, and vaccine research. It serves as a vital link between global pharmaceutical sponsors and the Kansas City patient community, offering advanced diagnostic and treatment options through research protocols. The site is staffed by board-certified physicians and experienced research professionals dedicated to maintaining rigorous regulatory and data standards. AMR Kansas City is equipped to handle a wide range of therapeutic modalities, including small molecules, biologics, and complex cell-based therapies.